Hepatitis B is a serious public health problem in China. In the past 10 years, with the development of medicine, great progress has been made in the prevention and treatment of hepatitis B. However, there are still many misconceptions about hepatitis B, which bring many unnecessary fears and great psychological pressure to the public and hepatitis B patients. The misconceptions about hepatitis B “major tri-positive” and “minor tri-positive” are more common: the “major tri-positive” is a sign of seriousness and cannot be treated, while the “minor tri-positive” is a sign of seriousness. The “small three yang” means that the disease has been alleviated and is not very relevant without treatment, etc. At present, there are many methods to detect hepatitis B virus infection, of which the most commonly used and most common is the hepatitis B five-item (also known as “two-and-a-half”) test. The most common clinical test is the five tests for hepatitis B virus (also known as “two-to-one”), i.e. Hepatitis B virus surface antigen (HBsAg) Hepatitis B virus surface antibody (anti-HBs) Hepatitis B virus e antigen (HBeAg) Hepatitis B virus e antibody (anti-HBe) Hepatitis B virus core antibody (anti-HBc) In layman’s terms: the antigen is part of the hepatitis B virus; the antibody is produced by the body to fight the hepatitis B virus. The so-called “major triple-positive” is the common name for people who have three positive HBsAg, HBeAg, and anti-HBc tests and two negative ones; the so-called “minor triple-positive” is the common name for people who have positive HBsAg, anti-HBe, and anti-HBc tests and two negative ones. The other two are negative. The “major triplet” is HBeAg (+) anti-HBe (-) The “minor triplet” is HBeAg (-) anti-HBe (+) II. Clinical significance of “major tri-positive” and “minor tri-positive” Hepatitis B “major tri-positive” and “minor tri-positive” are characterized by HBeAg/anti-HBe positive or negative to distinguish, therefore, its clinical significance is related to HBeAg/anti-HBe positive or negative. HBeAg is a soluble component of the hepatitis B virus core antigen, often present along with serum hepatitis B virus nucleic acid (HBVDNA), and is a marker of hepatitis B virus replication and infectivity. The “major triplet” can be seen in: early stage of acute hepatitis B, chronic hepatitis B, asymptomatic HBsAg carriers and some patients with cirrhosis and liver cancer. Some chronically infected patients can naturally turn negative with HBeAg as they age. The annual natural negative rate of HBeAg in chronic hepatitis B patients is about 25.6% and in asymptomatic carriers is about 9.3%. Anti-HBe is an antibody produced by the body’s immune system against HBeAg and appears after the HBeAg has turned negative. The appearance of anti-HBe indicates a reduction in viral replication, a decrease in infectivity, and a stabilization of the patient’s condition. In the past, anti-HBe was considered to be an indicator of recovery or non-infectiousness of HBV infection. In recent years, studies have found that anti-HBe positive sera may still be infectious, but they are far less infectious than HBeAg positive sera. Some patients can still have recurrent disease. HBeAg is not necessarily a sign of chronic hepatitis B activity, and anti-HBe is not necessarily an indicator of healthy carriage. The relationship between hepatitis B “major tri-positive” and “minor tri-positive” and the patient’s condition There is no obvious direct relationship between hepatitis B “major tri-positive” and “minor tri-positive” and the patient’s condition. The analysis of “major triplet” and “minor triplet” alone does not indicate the severity of the patient’s condition, i.e. the degree of liver damage. The clinical examination of the five hepatitis B tests allows us to understand the presence and replication of the hepatitis B virus in the human body. In the case of “major triple yang”, the hepatitis B virus is more actively replicating than in the case of “minor triple yang” and is relatively more infectious. Since the hepatitis B virus causes damage to human liver cells mainly through the complex immune-mediated mechanism of the body, rather than the hepatitis B virus directly damages liver cells. There is no obvious parallel between the severity of the disease in hepatitis B patients and the amount of HBeAg positivity and the amount of hepatitis B virus in the blood.” Patients with “major triple-positive” may not have any liver function damage or any clinical manifestations, but only appear to be healthy carriers of hepatitis B virus, while patients with chronic hepatitis, cirrhosis, liver cancer, or even very severe severe hepatitis may be “minor triple-positive”. The severity of hepatitis B can only be concluded through a comprehensive analysis of the patient’s clinical manifestations, liver function, ultrasound and pathological histological examination, and not based on the “major and minor triplets”. Therefore, it is one-sided and unscientific to judge the severity of a patient’s condition by “major tri-positive” and “minor tri-positive”. The treatment of hepatitis B “big three yang” and “small three yang” At present, the treatment of hepatitis B is still a worldwide problem, and there is not yet an effective anti-hepatitis B virus drug at home and abroad. Therefore, the treatment of patients with “major triplets” and “minor triplets” should be treated on a case-by-case basis. In principle, if there is liver function impairment in either “major triple-positive” or “minor triple-positive” patients, appropriate and reasonable liver-protective treatment should be carried out under the guidance of a physician, while paying attention to rest and a reasonable diet, as well as immunomodulatory and antiviral treatment if necessary. If there are no obvious clinical manifestations and the liver function is normal, no special treatment is necessary and regular observation is sufficient. Generally, liver function and liver ultrasound should be reviewed every 3-6 months. If there is any problem in the review, treatment will be prompt.